Prof Aron Goldhirsch MD
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
MD, Prof Aron Goldhirsch; PhD, Prof Richard D Gelber; MD, Prof Martine J Piccart-Gebhart; MD, Evandro de Azambuja; MSci, Marion Procter; MD, Prof Thomas M Suter; MD, Prof Christian Jackisch; MD, Prof David Cameron; MD, Harald A Weber; PhD, Dominik Heinzmann; MD, Lissandra Dal Lago; MA, Eleanor McFadden; PhD, Prof Mitch Dowsett; MD, Prof Michael Untch; MD, Luca Gianni; MD, Prof Richard Bell; MD, Prof Claus-Henning Köhne; MD, Anita Vindevoghel; MD, Michael Andersson; MD, A Murray Brunt; MD, Douglas Otero-Reyes; MD, Santai Song; MD, Prof Ian Smith; PhD †, Brian Leyland-Jones; MD †, Prof Jose Baselga
Authors
Prof Richard D Gelber PhD
Prof Martine J Piccart-Gebhart MD
Evandro de Azambuja MD
Marion Procter MSci
Prof Thomas M Suter MD
Prof Christian Jackisch MD
Prof David Cameron MD
Harald A Weber MD
Dominik Heinzmann PhD
Lissandra Dal Lago MD
Eleanor McFadden MA
Prof Mitch Dowsett PhD
Prof Michael Untch MD
Luca Gianni MD
Prof Richard Bell MD
Prof Claus-Henning Köhne MD
Anita Vindevoghel MD
Michael Andersson MD
Professor Adrian Brunt m.brunt@keele.ac.uk
Douglas Otero-Reyes MD
Santai Song MD
Prof Ian Smith MD
Brian Leyland-Jones PhD †
Prof Jose Baselga MD †
Citation
MD, P. A. G., PhD, P. R. D. G., MD, P. M. J. P.-G., MD, E. D. A., MSci, M. P., MD, P. T. M. S., MD, P. C. J., MD, P. D. C., MD, H. A. W., PhD, D. H., MD, L. D. L., MA, E. M., PhD, P. M. D., MD, P. M. U., MD, L. G., MD, P. R. B., MD, P. C.-H. K., MD, A. V., MD, M. A., MD, A. M. B., …MD †, P. J. B. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/S0140-6736%2813%2961094-6
Journal Article Type | Article |
---|---|
Publication Date | Sep 21, 2013 |
Deposit Date | Jun 5, 2023 |
Journal | LANCET |
Print ISSN | 0140-6736 |
Electronic ISSN | 1474-547X |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 382 |
Issue | 9897 |
Pages | 1021-1028 |
DOI | https://doi.org/10.1016/S0140-6736%2813%2961094-6 |
Public URL | https://keele-repository.worktribe.com/output/438941 |
You might also like
Hypofractionation: The standard for external beam breast irradiation
(2023)
Journal Article
Hypofractionation: The standard for external beam breast irradiation
(2023)
Journal Article
Breast cancer radiation therapy - Authors' reply.
(2020)
Journal Article
FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results
(2020)
Journal Article
Downloadable Citations
About Keele Repository
Administrator e-mail: research.openaccess@keele.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search